International Assets Investment Management LLC Invests $393,000 in Genmab A/S (NASDAQ:GMAB)

International Assets Investment Management LLC purchased a new position in shares of Genmab A/S (NASDAQ:GMAB) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 12,513 shares of the company’s stock, valued at approximately $393,000.

Several other hedge funds also recently modified their holdings of GMAB. Headlands Technologies LLC acquired a new position in Genmab A/S in the 3rd quarter valued at $27,000. NBC Securities Inc. bought a new position in Genmab A/S during the 3rd quarter valued at about $37,000. China Universal Asset Management Co. Ltd. lifted its holdings in Genmab A/S by 86.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company’s stock valued at $38,000 after purchasing an additional 498 shares during the last quarter. UMB Bank n.a. lifted its holdings in Genmab A/S by 234.4% during the 3rd quarter. UMB Bank n.a. now owns 1,478 shares of the company’s stock valued at $52,000 after purchasing an additional 1,036 shares during the last quarter. Finally, Exchange Traded Concepts LLC lifted its holdings in Genmab A/S by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 3,691 shares of the company’s stock valued at $118,000 after purchasing an additional 936 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Trading Up 2.5 %

Shares of NASDAQ:GMAB opened at $28.15 on Friday. The stock’s fifty day simple moving average is $29.44 and its two-hundred day simple moving average is $30.08. Genmab A/S has a 1-year low of $26.32 and a 1-year high of $42.72. The stock has a market cap of $18.61 billion, a PE ratio of 29.32, a price-to-earnings-growth ratio of 2.04 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.02. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. The business had revenue of $675.29 million for the quarter, compared to analysts’ expectations of $678.14 million. On average, sell-side analysts forecast that Genmab A/S will post 1.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. BMO Capital Markets upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $46.00 to $48.00 in a research report on Friday, February 23rd. Citigroup lowered shares of Genmab A/S from a “neutral” rating to a “sell” rating in a research report on Monday, January 22nd. Truist Financial reissued a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research report on Tuesday, March 26th. Morgan Stanley reaffirmed an “underweight” rating on shares of Genmab A/S in a research report on Tuesday, March 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Thursday, April 4th. Three analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $48.50.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.